DOCSLIB.ORG

GX15–070 (Obatoclax)

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
GX15–070 (Obatoclax) Cournoyer et al. BMC Cancer (2019) 19:1018 https://doi.org/10.1186/s12885-019-6195-y RESEARCH ARTICLE Open Access GX15–070 (Obatoclax), a Bcl-2 family proteins inhibitor engenders apoptosis and pro-survival autophagy and increases Chemosensitivity in neuroblastoma Sonia Cournoyer1, Anissa Addioui1,2, Assila Belounis1,2, Mona Beaunoyer1,3, Carine Nyalendo1, Roxane Le Gall1, Pierre Teira1,4, Elie Haddad1, Gilles Vassal5 and Hervé Sartelet1,2,6* Abstract Background: Neuroblastoma (NB) is a frequent pediatric tumor associated with poor prognosis. The disregulation of Bcl-2, an anti-apoptotic protein, is crucial for the tumoral development and chemoresistance. Autophagy is also implicated in tumor cell survival and chemoresistance. The aim of our study was to demonstrate therapeutic efficiency of GX 15–070, a pan-Bcl-2 family inhibitor, used alone and in combination with conventional drugs or with hydroxychloroquine (HCQ), an autophagy inhibitor. Methods: Five neuroblastoma cell lines were tested for the cytotoxic activity of GX 15–070 alone or in combination with cisplatin, doxorubicin, HCQ or Z-VAD-FMK a broad-spectrum caspase inhibitor. Apoptosis and autophagy levels were studied by western-blot and FACS. Orthotopic injections were performed on NOD/LtSz-scid/IL-2Rgamma null mice that were treated with either GX 15–070 alone or in combination with HCQ. Results: Synergistic cytotoxicity was observed for the drug combination in all of the 5 neuroblastoma cell lines tested, including MYCN amplified lines and in cancer stem cells. GX 15–070 significantly increased apoptosis and autophagy in neuroblastoma cells as evidenced by increased levels of the autophagy marker, LC3-II. Inhibition of autophagy by HCQ, further increased the cytotoxicity of this combinatorial treatment, suggesting that autophagy induced by these agent plays a cytoprotective role. In vivo, GX 15–070 combined with HCQ significantly decreased the growth of the tumor and the number of distant metastases. Conclusions: Based on the synergistic effect of HCQ and GX 15–070 observed in this study, the combination of these two drugs may be utilized as a new therapeutic approach for neuroblastoma. Keywords: Bcl-2, Neuroblastoma, Apoptosis, Autophagy, GX15–070 Background [1]. Indeed, according to clinical, biological and patho- Neuroblastoma (NB) is a pediatric tumor of the sympa- logical tumor datas, patients with tumors classified in thetic nervous system, with a median age of 17 months the low-risk group present a good survival and can show at diagnosis it is responsible for over 15% of pediatric a spontanous tumor regression while in patients with cancer deaths [1]. In 50% of patients, it localises in in high-risk NB, the long term survival is poor despite ag- the adrenal medulla or paraspinal ganglia [1]. The NB is gressive chemotherapy and radiotherapy treatments, and caracterised by it’s clinical and biological heterogeneity stem cells transplants [2]. It is therefore essential to de- velop new therapeutic strategies to improve the survival * Correspondence: [email protected] of patients with high-risk NB. 1Research Center, Sainte Justine University Hospital Center, Montreal, QC, Canada The concept of cancers stem cells (CSCs) appears rele- 2Department of Pathology and Cellular Biology, Université de Montréal, vant to explain the high level of metastasis, chemoresis- Montreal, QC, Canada tance and unfavorable prognosis commonly observed in Full list of author information is available at the end of the article © The Author(s). 2019 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. Cournoyer et al. BMC Cancer (2019) 19:1018 Page 2 of 14 NB. Many studies suggest that malignant tumors contain These CSCs are thought to be responsible for metastasis subpopulations of cells that share characteristics with and are more resistant to chemotherapeutic agents, normal stem cells, that is, they are capable of self- thereby permitting the recurrence of tumors after renewal, differentiation, and initiation of tumors [3]. chemotherapy and radiotherapy [4]. CD133 has been Fig. 1 a Basal level expression of important pro and antiapoptotic BCL-2 family proteins in human neuroblastoma. β-actin served as loading control. b. The effect of GX 15–070 used in monotherapy in NB cell viability in vitro. IGR-NB8, IGR-91, NB-10, SK-N-DZ and SK-N-FI cells treated 24 and 48 h with increasing concentrations of GX 15–070 (0.078 μM, 0.15 μM, 0.3 μM, 0.6 μM, and 5 μM).were added to the medium for 24 and 48 h and cell viability determined by the standard methyl-thiazoldiphenyl tetrazolium (MTT) assay. Each value represents the mean ± SEM (n =3) Cournoyer et al. BMC Cancer (2019) 19:1018 Page 3 of 14 identified as a marker of a subset of neural stem cells in resistance. GX 15–070 with its large spectrum of in- the adult central nervous system as well as of glioblast- hibition including Mcl-1 represents a potential inter- oma stem-like cells [5, 6]. In NB, CD133 expression is est in the treatment of NB. In other tumors, in vitro associated with poor prognosis, chemoresistance [7] and preclinical studies have shown efficacy of GX 15– the cells expressing this protein present stemness prop- 070 as monotherapy or in combination with other erty [8]. anticancer agents like in refractory mantle cell Apoptosis, also called programmed cell death, is es- lymphoma [20] or in antiestrogen-resistant breast sential for the normal regulation of cell survival by cancer cells [21]. Moreover, GX 15–070 selectively suppressing superfluous or damaged cells. A defect in eradicates quiescent human leukemia stem cells [22] the apoptosic pathway is now considered to be the and radiosensitizes glioblastoma stem-like cells [23]. foundation of most cancers [9]. Apoptosis occurs in Another mechanism implicated in tumor cell response to the disturbance of one of the two inter- survival and drug resistance is autophagy whitch is connected pathways known to be the extrinsinc death activated by metabolic stress [24, 25]. This lysosomal receptors or the intrinsic mitochondrial pathway. The degrative pathway, caracterised by autophagosomes mitochondrial pathway of apoptosis is regulated by formation, seems to be involved in the unsuccessful Bcl-2 family proteins which regulate cell survival and therapeutic effectiveness because of tumor masses is comprised of Bcl-2, Bcl-XL, Bcl-W, Bcl-2-A1, and vessel, nutrient heterogenecities, and hypoxic tumor Mcl-1. Studies show that deregulation of the Bcl-2 as regions that undergo autophagy. Since several studies primary oncogenic event (initiator) or secondary (pro- have shown that autophagy is crucial as a survival moter) is crucial for the tumoral development, main- mechanism in different tumors with defects in the tenance and chemoresistance [10]. In NB, in vitro apoptotic pathway, the modulation of these pathways studies have demonstrated that Bcl-2 is highly could be an interesting avenue for improvement of expressed, and its expression is inversely correlated to NB treatments [26]. Autophagy contributes to modu- the number of apoptotic cells and the level of differ- lating the cytotoxicities of Bcl-2 homology domain-3 entiation of the tumor [11]. Also, overexpression of mimetics [27]. Beclin 1, a Bcl-2 homology 3 (BH3) Bcl-2 in NB cell lines is associated with chemoresis- domain only protein is an essential initiator of au- tance [12]. The high level of expression of Bcl-2 is tophagy. In addition, Beclin 1 is a key determining also correlated with unfavorable histology, MYCN factor as to whether cells undergo autophagy or apop- amplification and poor prognosis [12]. The analysis of tosis [28]. Beclin 1 has been shown to interact via its the anti-apoptotic protein Bcl-2 and Mcl-1 have dem- BH3 domain with Bcl-2 family members. The dual onstrated a strong expression in NB [13]. It was role of Bcl-2 and Bcl-xL in inhibiting both apoptosis shown that the anti-apoptotic genes such as Bcl-2 and autophagic-associated cell death makes these pro- and Bcl-xL were overexpressed in CSC while the ex- teins ideal chemotherapeutic targets. BH3 mimetics, pression of pro-apoptotic genes such as Bax were GX 15–070 and ABT-737, disrupt the Bcl-2-Beclin1 downregulated in CSC of glioblastoma [14]. Also, interaction. GX15–070 induces pro-survival autophagy overexpression of Bcl-2 gene contribute to the resist- in head and neck squamous cell carcinoma cells [29] ance of medulloblastoma CSC to radiotherapy [15]. whereas the combination of GX15–070 with chloro- Therefore, Bcl-2 is an attractive target in the treat- quine, a specific autophagy inhibitor, results in syner- ment of NB. Bcl-2 inhibitor could be used alone or in gistic cytotoxicity against pancreatic cancer cells [20]. combination with others drugs to potentiate treat- The aim of our study was to evaluate the activity ment efficiency [16]. of Obatoclax against NB cells used in monotherapy GX 15–070, by activating the intrinsic pathway of or in combination with conventional drugs or with apoptosis, is an inhibitor of all anti-apoptotic Bcl-2 an autophagy inhibitor, hydroxychloroquine (HCQ). proteins. GX 15–070 inhibits specifically Bcl-XL, Bcl-2, MCL-1, Bcl-w, A1 and Bcl-B [17]. Recent – study desmonstrated that NB cell lines and primary Table 1 IC50 of NB cell lines treated with GX 15 070 μ μ tumors are primed for death with sequestration of NB cell IC50 ( M) IC50 ( M) lines Bim, a direct activator of apoptosis, by either Bcl-2 24 h 48 h or Mcl-1, providing a survival dependency that pre- SK-N-DZ 0,213 0,164 dicts the activity of Bcl-2 antagonists [18].
Load more

Recommended publications
  • How I Treat Myelofibrosis
    From www.bloodjournal.org by guest on October 7, 2014. For personal use only. Prepublished online September 16, 2014; doi:10.1182/blood-2014-07-575373 How I treat myelofibrosis Francisco Cervantes Information about reproducing this article in parts or in its entirety may be found online at: http://www.bloodjournal.org/site/misc/rights.xhtml#repub_requests Information about ordering reprints may be found online at: http://www.bloodjournal.org/site/misc/rights.xhtml#reprints Information about subscriptions and ASH membership may be found online at: http://www.bloodjournal.org/site/subscriptions/index.xhtml Advance online articles have been peer reviewed and accepted for publication but have not yet appeared in the paper journal (edited, typeset versions may be posted when available prior to final publication). Advance online articles are citable and establish publication priority; they are indexed by PubMed from initial publication. Citations to Advance online articles must include digital object identifier (DOIs) and date of initial publication. Blood (print ISSN 0006-4971, online ISSN 1528-0020), is published weekly by the American Society of Hematology, 2021 L St, NW, Suite 900, Washington DC 20036. Copyright 2011 by The American Society of Hematology; all rights reserved. From www.bloodjournal.org by guest on October 7, 2014. For personal use only. Blood First Edition Paper, prepublished online September 16, 2014; DOI 10.1182/blood-2014-07-575373 How I treat myelofibrosis By Francisco Cervantes, MD, PhD, Hematology Department, Hospital Clínic, IDIBAPS, University of Barcelona, Barcelona, Spain Correspondence: Francisco Cervantes, MD, Hematology Department, Hospital Clínic, Villarroel 170, 08036 Barcelona, Spain. Phone: +34 932275428.
    [Show full text]
  • Targeting BCL-2 in Cancer: Advances, Challenges, and Perspectives
    cancers Review Targeting BCL-2 in Cancer: Advances, Challenges, and Perspectives Shirin Hafezi 1 and Mohamed Rahmani 1,2,* 1 Research Institute of Medical & Health Sciences, University of Sharjah, P.O. Box 27272 Sharjah, United Arab Emirates; [email protected] 2 Department of Basic Medical Sciences, College of Medicine, University of Sharjah, P.O. Box 27272 Sharjah, United Arab Emirates * Correspondence: [email protected]; Tel.: +971-6505-7759 Simple Summary: Apoptosis, a programmed form of cell death, represents the main mechanism by which cells die. Such phenomenon is highly regulated by the BCL-2 family of proteins, which includes both pro-apoptotic and pro-survival proteins. The decision whether cells live or die is tightly controlled by a balance between these two classes of proteins. Notably, the pro-survival Bcl-2 proteins are frequently overexpressed in cancer cells dysregulating this balance in favor of survival and also rendering cells more resistant to therapeutic interventions. In this review, we outlined the most important steps in the development of targeting the BCL-2 survival proteins, which laid the ground for the discovery and the development of the selective BCL-2 inhibitor venetoclax as a therapeutic drug in hematological malignancies. The limitations and future directions are also discussed. Abstract: The major form of cell death in normal as well as malignant cells is apoptosis, which is a programmed process highly regulated by the BCL-2 family of proteins. This includes the antiapoptotic proteins (BCL-2, BCL-XL, MCL-1, BCLW, and BFL-1) and the proapoptotic proteins, which can be divided into two groups: the effectors (BAX, BAK, and BOK) and the BH3-only proteins Citation: Hafezi, S.; Rahmani, M.
    [Show full text]
  • Discovery of Mcl-1 Inhibitors from Integrated High Throughput and Virtual Screening Received: 9 March 2018 Ahmed S
    www.nature.com/scientificreports OPEN Discovery of Mcl-1 inhibitors from integrated high throughput and virtual screening Received: 9 March 2018 Ahmed S. A. Mady1,3, Chenzhong Liao1,8, Naval Bajwa1,9, Karson J. Kump1,4, Accepted: 5 June 2018 Fardokht A. Abulwerdi 1,3,10, Katherine L. Lev1, Lei Miao 1, Sierrah M. Grigsby1,2, Published: xx xx xxxx Andrej Perdih5, Jeanne A. Stuckey6, Yuhong Du7, Haian Fu 7 & Zaneta Nikolovska-Coleska1,2,3,4 Protein-protein interactions (PPIs) represent important and promising therapeutic targets that are associated with the regulation of various molecular pathways, particularly in cancer. Although they were once considered “undruggable,” the recent advances in screening strategies, structure-based design, and elucidating the nature of hot spots on PPI interfaces, have led to the discovery and development of successful small-molecule inhibitors. In this report, we are describing an integrated high-throughput and computational screening approach to enable the discovery of small-molecule PPI inhibitors of the anti- apoptotic protein, Mcl-1. Applying this strategy, followed by biochemical, biophysical, and biological characterization, nineteen new chemical scafolds were discovered and validated as Mcl-1 inhibitors. A novel series of Mcl-1 inhibitors was designed and synthesized based on the identifed difuryl-triazine core scafold and structure-activity studies were undertaken to improve the binding afnity to Mcl- 1. Compounds with improved in vitro binding potency demonstrated on-target activity in cell-based studies. The obtained results demonstrate that structure-based analysis complements the experimental high-throughput screening in identifying novel PPI inhibitor scafolds and guides follow-up medicinal chemistry eforts.
    [Show full text]
  • BCL-2 Inhibitors for Chronic Lymphocytic Leukemia
    L al of euk rn em u i o a J Robak, J Leuk 2015, 3:3 Journal of Leukemia DOI: 10.4172/2329-6917.1000e114 ISSN: 2329-6917 Editorial Open access BCL-2 inhibitors for Chronic Lymphocytic Leukemia Tadeusz Robak* Department of Hematology, Medical University of Lodz, 93-510 Lodz, ul, Ciolkowskiego 2, Poland *Corresponding author: Tadeusz Robak, Department of Hematology, Medical University of Lodz, Copernicus Memorial Hospital, 93-510 Lodz, Ul. Ciolkowskiego 2, Poland, Tel: +48 42 6895191; E-mail: [email protected] Rec date: August 10, 2015; Acc date: August 12, 2015; Pub date: August 24, 2015 Copyright: © 2015 Robak T. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Editorial cyclophosphamide and rituximab (FCR) or bendamustin-rituximab (BR) regimens in refractory CLL are ongoing (NCT00868413). B-cell chronic lymphocytic leukemia (CLL) is the most common adult leukemia in Europe and North America, with an annual Venetoclax ( GDC-0199, ABT-199, RG7601; Genentech, South San incidence of three to five cases per 100,000 [1]. The approval of Francisco, CA), is a first-in-class, orally bioavailable BCL-2 family rituximab-based immunochemotherapy represented a substantial protein inhibitor that binds with high affinity to BCL-2 and with lower therapeutic advance in CLL [2]. However, currently available therapies affinity to the other BCL-2 family proteins Bcl-xL, Bcl-w and Mcl-1 are only partially efficient, and there is an obvious need to develop [14].
    [Show full text]
  • Phenotype-Based Drug Screening Reveals Association Between Venetoclax Response and Differentiation Stage in Acute Myeloid Leukemia
    Acute Myeloid Leukemia SUPPLEMENTARY APPENDIX Phenotype-based drug screening reveals association between venetoclax response and differentiation stage in acute myeloid leukemia Heikki Kuusanmäki, 1,2 Aino-Maija Leppä, 1 Petri Pölönen, 3 Mika Kontro, 2 Olli Dufva, 2 Debashish Deb, 1 Bhagwan Yadav, 2 Oscar Brück, 2 Ashwini Kumar, 1 Hele Everaus, 4 Bjørn T. Gjertsen, 5 Merja Heinäniemi, 3 Kimmo Porkka, 2 Satu Mustjoki 2,6 and Caroline A. Heckman 1 1Institute for Molecular Medicine Finland, Helsinki Institute of Life Science, University of Helsinki, Helsinki; 2Hematology Research Unit, Helsinki University Hospital Comprehensive Cancer Center, Helsinki; 3Institute of Biomedicine, School of Medicine, University of Eastern Finland, Kuopio, Finland; 4Department of Hematology and Oncology, University of Tartu, Tartu, Estonia; 5Centre for Cancer Biomarkers, De - partment of Clinical Science, University of Bergen, Bergen, Norway and 6Translational Immunology Research Program and Department of Clinical Chemistry and Hematology, University of Helsinki, Helsinki, Finland ©2020 Ferrata Storti Foundation. This is an open-access paper. doi:10.3324/haematol. 2018.214882 Received: December 17, 2018. Accepted: July 8, 2019. Pre-published: July 11, 2019. Correspondence: CAROLINE A. HECKMAN - [email protected] HEIKKI KUUSANMÄKI - [email protected] Supplemental Material Phenotype-based drug screening reveals an association between venetoclax response and differentiation stage in acute myeloid leukemia Authors: Heikki Kuusanmäki1, 2, Aino-Maija
    [Show full text]
  • Identifying the Druggable Interactome of EWS-FLI1 Reveals MCL-1 Dependent Differential Sensitivities of Ewing Sarcoma Cells to Apoptosis Inducers
    www.oncotarget.com Oncotarget, 2018, Vol. 9, (No. 57), pp: 31018-31031 Research Paper Identifying the druggable interactome of EWS-FLI1 reveals MCL-1 dependent differential sensitivities of Ewing sarcoma cells to apoptosis inducers Kalliopi Tsafou1,7,*, Anna Maria Katschnig3,*, Branka Radic-Sarikas2,3,*, Cornelia Noëlle Mutz3, Kristiina Iljin5, Raphaela Schwentner3, Maximilian O. Kauer3, Karin Mühlbacher3, Dave N.T. Aryee3,4, David Westergaard1, Saija Haapa-Paananen5, Vidal Fey5, Giulio Superti-Furga2, Jeffrey Toretsky6, Søren Brunak1 and Heinrich Kovar3,4 1Disease Systems Biology, Novo Nordisk Foundation Center for Protein Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark 2CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria 3Children’s Cancer Research Institute, St. Anna Kinderkrebsforschung, Vienna, Austria 4Department of Pediatrics, Medical University of Vienna, Vienna, Austria 5Medical Biotechnology, VTT Technical Research Centre of Finland, Espoo, Finland 6Department of Oncology, Georgetown University, Medical Center, Washington, DC, USA 7Current address: Broad Institute of MIT and Harvard, Cambridge, MA, USA *These authors contributed equally to this work Correspondence to: Heinrich Kovar, email: [email protected] Keywords: high-throughput compound screening; Ewing sarcoma; drug-target network; apoptosis; BCL-2 inhibitors Received: March 07, 2018 Accepted: June 22, 2018 Published: July 24, 2018 Copyright: Tsafou et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License 3.0 (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. ABSTRACT Ewing sarcoma (EwS) is an aggressive pediatric bone cancer in need of more effective therapies than currently available.
    [Show full text]
  • WO 2017/223239 Al 28 December 2017 (28.12.2017) W !P O PCT
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization I International Bureau (10) International Publication Number (43) International Publication Date WO 2017/223239 Al 28 December 2017 (28.12.2017) W !P O PCT (51) International Patent Classification: Published: A61K 31/445 (2006.01) C07D 471/04 (2006.01) — with international search report (Art. 21(3)) A61K 31/437 {2006.01) — before the expiration of the time limit for amending the (21) International Application Number: claims and to be republished in the event of receipt of PCT/US20 17/038609 amendments (Rule 48.2(h)) (22) International Filing Date: 2 1 June 2017 (21 .06.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/352,820 2 1 June 2016 (21 .06.2016) 62/456,526 08 February 2017 (08.02.2017) (71) Applicant: X4 PHARMACEUTICALS, INC. [US/US]; 955 Massachusetts Avenue; 4th Floor, Cambridge, Massa chusetts 02139 (US). (72) Inventors: BOURQUE, Elyse Marie Josee; 3115 Racine Street, Unit 214, Bellingham, Washington 98226 (US). SK- ERLJ, Renato; 12 Crocker Circle, West Newton, Massa chusetts 02465 (US). (74) Agent: REID, Andrea L., C. et al; One International Place, 40th Floor, 100 Oliver Street, Boston, Massachusetts 021 10-2605 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
    [Show full text]
  • Obatoclax Kills Anaplastic Thyroid Cancer Cells by Inducing Lysosome Neutralization and Necrosis
    www.impactjournals.com/oncotarget/ Oncotarget, Vol. 7, No. 23 Obatoclax kills anaplastic thyroid cancer cells by inducing lysosome neutralization and necrosis Devora Champa1, Arturo Orlacchio1, Bindi Patel1, Michela Ranieri1, Anton A Shemetov2, Vladislav V Verkhusha2, Ana Maria Cuervo1, Antonio Di Cristofano1 1Department of Developmental and Molecular Biology, Albert Einstein College of Medicine, Bronx, NY 10461, USA 2Department of Anatomy and Structural Biology, Albert Einstein College of Medicine, Bronx, NY 10461, USA Correspondence to: Antonio Di Cristofano, email: [email protected] Keywords: thyroid cancer, lysosomes, necrosis, autophagy, obatoclax Received: March 16, 2016 Accepted: April 16, 2016 Published: April 30, 2016 ABSTRACT Poorly differentiated and anaplastic thyroid carcinomas are very aggressive, almost invariably lethal neoplasms for which no effective treatment exists. These tumors are intrinsically resistant to cell death, even when their driver oncogenic signaling pathways are inhibited. We have undertaken a detailed analysis, in mouse and human thyroid cancer cells, of the mechanism through which Obatoclax, a pan-inhibitor of the anti-apoptotic proteins of the BCL2 family, effectively reduces tumor growth in vitro and in vivo. We demonstrate that Obatoclax does not induce apoptosis, but rather necrosis of thyroid cancer cells, and that non-transformed thyroid cells are significantly less affected by this compound. Surprisingly, we show that Obatoclax rapidly localizes to the lysosomes and induces loss of acidification, block of lysosomal fusion with autophagic vacuoles, and subsequent lysosomal permeabilization. Notably, prior lysosome neutralization using different V-ATPase inhibitors partially protects cancer cells from the toxic effects of Obatoclax. Although inhibition of autophagy does not affect Obatoclax-induced cell death, selective down-regulation of ATG7, but not of ATG5, partially impairs Obatoclax effects, suggesting the existence of autophagy- independent functions for ATG7.
    [Show full text]
  • Identification of Anisomycin, Prodigiosin and Obatoclax As Compounds with Broad-Spectrum Anti-Parasitic Activity
    UCSF UC San Francisco Previously Published Works Title Identification of anisomycin, prodigiosin and obatoclax as compounds with broad-spectrum anti-parasitic activity. Permalink https://escholarship.org/uc/item/9qz9r8pc Journal PLoS neglected tropical diseases, 14(3) ISSN 1935-2727 Authors Ehrenkaufer, Gretchen Li, Pengyang Stebbins, Erin E et al. Publication Date 2020-03-20 DOI 10.1371/journal.pntd.0008150 Peer reviewed eScholarship.org Powered by the California Digital Library University of California PLOS NEGLECTED TROPICAL DISEASES RESEARCH ARTICLE Identification of anisomycin, prodigiosin and obatoclax as compounds with broad- spectrum anti-parasitic activity Gretchen Ehrenkaufer1, Pengyang Li2, Erin E. Stebbins3, Monica M. Kangussu- 1 4 5 5 5 Marcolino , Anjan Debnath , Corin V. White , Matthew S. MoserID , Joseph DeRisi , 6 6,7,8 4 4 Jolyn Gisselberg , Ellen Yeh , Steven C. WangID , Ana Hervella Company , Ludovica Monti4, Conor R. Caffrey4, Christopher D. Huston3, Bo Wang2,9, 1,7 Upinder SinghID * a1111111111 a1111111111 1 Division of Infectious Diseases, Department of Internal Medicine, Stanford University, Stanford, CA, United States of America, 2 Department of Bioengineering, Stanford University, Stanford, CA, United States of a1111111111 America, 3 Department of Medicine, University of Vermont Larner College of Medicine, Burlington, Vermont, a1111111111 United States of America, 4 Center for Discovery and Innovation in Parasitic Diseases, Skaggs School of a1111111111 Pharmacy and Pharmaceutical Sciences, University of California,
    [Show full text]
  • Biotechnological Activities and Applications of Bacterial Pigments Violacein and Prodigiosin Seong Yeol Choi1†, Sungbin Lim1†, Kyoung-Hye Yoon2*, Jin I
    Choi et al. Journal of Biological Engineering (2021) 15:10 https://doi.org/10.1186/s13036-021-00262-9 REVIEW Open Access Biotechnological Activities and Applications of Bacterial Pigments Violacein and Prodigiosin Seong Yeol Choi1†, Sungbin Lim1†, Kyoung-hye Yoon2*, Jin I. Lee3* and Robert J. Mitchell1* Abstract In this review, we discuss violacein and prodigiosin, two chromogenic bacterial secondary metabolites that have diverse biological activities. Although both compounds were “discovered” more than seven decades ago, interest into their biological applications has grown in the last two decades, particularly driven by their antimicrobial and anticancer properties. These topics will be discussed in the first half of this review. The latter half delves into the current efforts of groups to produce these two compounds. This includes in both their native bacterial hosts and heterogeneously in other bacterial hosts, including discussing some of the caveats related to the yields reported in the literature, and some of the synthetic biology techniques employed in this pursuit. Keywords: Prodigiosin, Violacein, Antibacterial, Anticancer, Secondary Metabolite, Production, Synthetic Biology Introduction compound is their cost, which range from $360 to $760 Bacterial strains are capable of producing many different per milligram [4]. Within this review, therefore, discus- secondary metabolites, including anti-cancer and anti- sion will be given primarily to the biological activities of biotic drugs. Here, we discuss two such compounds that these compounds, focusing on ecological and medical are gaining interest due to their diverse biological activ- considerations of both violacein and prodigiosin, as well ities, namely violacein and prodigiosin. Both of these as current methods to over-produce these remarkable compounds are synthesized by Gram-negative hosts and compounds.
    [Show full text]
  • The Pan-Bcl-2 Inhibitor Obatoclax Promotes Differentiation and Apoptosis of Acute Myeloid Leukemia Cells
    Investigational New Drugs https://doi.org/10.1007/s10637-020-00931-4 PRECLINICAL STUDIES The pan-Bcl-2 inhibitor obatoclax promotes differentiation and apoptosis of acute myeloid leukemia cells Małgorzata Opydo-Chanek1 & Iwona Cichoń1 & Agnieszka Rak2 & Elżbieta Kołaczkowska1 & Lidia Mazur 1 Received: 4 January 2020 /Accepted: 26 March 2020 # The Author(s) 2020 Summary One of the key features of acute myeloid leukemia (AML) is the arrest of differentiation at the early progenitor stage of myelopoiesis. Therefore, the identification of new agents that could overcome this differentiation block and force leukemic cells to enter the apoptotic pathway is essential for the development of new treatment strategies in AML. Regarding this, herein we report the pro-differentiation activity of the pan-Bcl-2 inhibitor, obatoclax. Obatoclax promoted differentiation of human AML HL-60 cells and triggered their apoptosis in a dose- and time-dependent manner. Importantly, obatoclax-induced apoptosis was associated with leukemic cell differentiation. Moreover, decreased expression of Bcl-2 protein was observed in obatoclax-treated HL-60 cells. Furthermore, differentiation of these cells was accompanied by the loss of their proliferative capacity, as shown by G0/G1 cell cycle arrest. Taken together, these findings indicate that the anti-AML effects of obatoclax involve not only the induction of apoptosis but also differentiation of leukemic cells. Therefore, obatoclax represents a promising treatment for AML that warrants further exploration. Keywords Obatoclax
    [Show full text]
  • Inhibition of Anti-Apoptotic Bcl-2 Proteins in Preclinical and Clinical Studies: Current Overview in Cancer
    cells Review Inhibition of Anti-Apoptotic Bcl-2 Proteins in Preclinical and Clinical Studies: Current Overview in Cancer Simona D’Aguanno * and Donatella Del Bufalo Preclinical Models and New Therapeutic Agents Unit, IRCCS Regina Elena National Cancer Institute, 00144 Rome, Italy; [email protected] * Correspondence: [email protected]; Tel.: +39-0652666891 Received: 28 April 2020; Accepted: 19 May 2020; Published: 21 May 2020 Abstract: The dynamic interplay between pro-death and pro-survival Bcl-2 family proteins is responsible for a cell’s fate. Due to the recognized relevance of this family in cancer progression and response to therapy, different efforts have made in recent years in order to develop small molecules able to target anti-apoptotic proteins such as Bcl-2, Bcl-xL and Mcl-1. The limitations of the first Bcl-2 family targeted drugs, regarding on-target and off-target toxicities, have been overcome with the development of venetoclax (ABT-199), the first BH3 mimetic inhibitor approved by the FDA. The purpose of this review is to discuss the state-of-the-art in the development of drugs targeting Bcl-2 anti-apoptotic proteins and to highlight the potential of their application as single agents or in combination for improving anti-cancer therapy, focusing in particular on solid tumors. Keywords: cancer; Bcl-2; inhibitors 1. Introduction Apoptosis is a deeply studied form of programmed cell death that triggers cells to suicide through proteolysis of some key cellular components, which renders cells prone to be recognized by phagocytes [1] The two mechanisms of apoptotic induction are the “death receptor” or “extrinsic” pathway activated by exogenous death-inducing ligands, and the “mitochondrial” or “intrinsic” pathway induced by stress conditions [1].
    [Show full text]